Sunitinib Malate

Name: Sunitinib Malate
Brand: Selleck Chemicals
SKU: S1042
Rating: 5 (90 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1042

90 publications

CAS No. 341031-54-7

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.

Selleck's Sunitinib Malate has been cited by 90 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2011, 478(7369):349-55

PubMed: 21993628 ( click the link to review the publication )

Mol Med Rep, 2021, 23(1)40

PubMed: 33179075 ( click the link to review the publication )

Nat Protoc, 2020, 15(2):421-449

PubMed: 31932771 ( click the link to review the publication )

Cancer Res, 2020, canres.1992.2020

PubMed: 33203698 ( click the link to review the publication )

J Clin Med, 2020, 9(3)

PubMed: 32131507 ( click the link to review the publication )

Front Oncol, 2020, 10:516552

PubMed: 33072561 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

FASEB J, 2019, 33(1):1347-1359

PubMed: 30148679 ( click the link to review the publication )

Oncoimmunology, 2019, 8(2):e1543526

PubMed: 30713805 ( click the link to review the publication )

Biomolecules, 2019, 9(11)

PubMed: 31683643 ( click the link to review the publication )

Expert Opin Ther Targets, 2019, 23(9):805-817

PubMed: 31385548 ( click the link to review the publication )

IEEE Trans Biomed Eng, 2019, 66(3):873-880

PubMed: 30059292 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Oncol Rep, 2019, 42(5):2039-2048

PubMed: 31485624 ( click the link to review the publication )

AAPS PharmSciTech, 2019, 20(7):281

PubMed: 31399890 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):625-631

PubMed: 31545912 ( click the link to review the publication )

Theranostics, 2018, 8(1):141-155

PubMed: 29290798 ( click the link to review the publication )

EBioMedicine, 2018, 27:225-236

PubMed: 29289530 ( click the link to review the publication )
Cancers (Basel), 2018, 10(10)E365

PubMed: 30274248 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

J Lipid Res, 2018, 59(11):2188-2201

PubMed: 30173145 ( click the link to review the publication )

Chem Biol Interact, 2018, 294:1-8

PubMed: 30125546 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Assay Drug Dev Technol, 2018, 16(7):408-419

PubMed: 29985634 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):1018

PubMed: 30282966 ( click the link to review the publication )

J Clin Invest, 2017, 127(4):1338-1352

PubMed: 28240606 ( click the link to review the publication )

Cancer Res, 2017, 77(4):1008-1020

PubMed: 28011623 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2502-2515

PubMed: 28729403 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

J Am Heart Assoc, 2017, 6(10)

PubMed: 29051215 ( click the link to review the publication )

J Biol Chem, 2017,

PubMed: 27903634 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68270-68279

PubMed: 28978115 ( click the link to review the publication )

Oncotarget, 2017, 9(1):802-811

PubMed: 29416656 ( click the link to review the publication )

Oncotarget, 2017, 8(13):20881-20894

PubMed: 28152509 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(33):9339-44

PubMed: 27482107 ( click the link to review the publication )

Oncogene, 2016, 35(21):2687-97

PubMed: 26364599 ( click the link to review the publication )

Dis Esophagus, 2016, 29(8):1144-1151

PubMed: 26542732 ( click the link to review the publication )

Oncol Lett, 2016, 12(6):4671-4676

PubMed: 28105174 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45015-45026

PubMed: 27304187 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )
Neurobiol Dis, 2015, 74:114-25

PubMed: 25461258 ( click the link to review the publication )

Exp Cell Res, 2015, 332(1):1-10

PubMed: 25637219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.04.107

PubMed: 25935484 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(9):2410-23

PubMed: 24573550 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(14):5319-24

PubMed: 24623852 ( click the link to review the publication )

Ann Surg, 2014, 259(4):793-9

PubMed: 24045439 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.29414

PubMed: 25556636 ( click the link to review the publication )

Oncogene, 2014, 33(19):2531-9

PubMed: 23728343 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5728-42

PubMed: 25091695 ( click the link to review the publication )

Br J Cancer, 2014, 111(6):1168-7

PubMed: 25093491 ( click the link to review the publication )

Neurobiol Dis, 2014, 10.1016/j.nbd.2014.10.024

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):89

PubMed: 25253994 ( click the link to review the publication )

Cancer Cell Int, 2014, 14:89

PubMed: ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Transl Oncol, 2014, 19(9):2368-80

PubMed: 23633458 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85759

PubMed: 24454929 ( click the link to review the publication )

PLoS One, 2014, 9(4):e96024

PubMed: 24770423 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6801-15

PubMed: 25149535 ( click the link to review the publication )

Cytometry A, 2014, 85(6):537-47

PubMed: 24664821 ( click the link to review the publication )
Cancer Res, 2013, 73(23):6886-99

PubMed: 24145351 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2018-30

PubMed: 23920274 ( click the link to review the publication )

Apoptosis, 2013, 19(4):682-97

PubMed: 24337903 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 377(1-2):1-6

PubMed: 23811235 ( click the link to review the publication )

Acta Oncol, 2013, 53(5):637-45

PubMed: 24041258 ( click the link to review the publication )

Am J Nucl Med Mol Imaging, 2013, 3(5):397-407

PubMed: 24116348 ( click the link to review the publication )

SENSOR ACTUAT B-CHEM, 2012, Jin Akagi

PubMed: ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Surgery, 2012, 152(6):1045-50

PubMed: 23102636 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

Cancer Res, 2011, 71(5):1637-46

PubMed: 21343392 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1897-908

PubMed: 21825009 ( click the link to review the publication )

Blood, 2010, 115(23):4725-33

PubMed: 20185585 ( click the link to review the publication )

Dis Model Mech, 2010, 3(5-6):343-53

PubMed: 20335444 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 398(2):205-11

PubMed: 20599738 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description

Targets

IRE1α ^[7] ()	Kit ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)	PDGFRβ ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
			2 nM	80 nM

In vitro

Sunitinib also potently inhibits Kit and FLT-3. ^[1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with K_i of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. ^[2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3	MmPLT4lv[XOnIFHzd4F6				MVrJcohq[mm2aX;uJI9nKFCGR1[tbY5lfWOnZDDCdoRWKGmwY3;ydI9z[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEC3JO69VQ>?	M3TsPVEzPjR4MEG5
3T3	M{[zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj4dWlyUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=>	M{HV[FEzPjR4MEG5
3T3	MVrGeY5kfGmxbjDBd5NigQ>?				MXfJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5Ihf2m2aDDJR\|UxKG:oIECuNFUh\|ryP	MoLkNVI3PDZyMUm=
3T3	MXXLbY5ie2ViQYPzZZk>		NITwV28zOCCvaX6=	MY\EUXNQ	NWXFcHZjS2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh\|ryP	NVvpdIVoOTZzNkKwNFg>
NIH3T3	M{T1c2tqdmG\|ZTDBd5NigQ>?		M1:1cFIxKG2rbh?=	NWe0fm41TE2VTx?=	MnvDbY5pcWKrdDDoeY1idiCNRGKgb4lv[XOnIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMUig{txO	M{X6blE3OTZ{MEC4
A549	NF;YNZNHfW6ldHnvckBCe3OjeR?=			M1y1VWROW09?	NYPMfIpmUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iQUW0PUBk\WyuIH3p[5JifGmxbjD3bZRpKEmFNUCgc4YhOiEQvF2=	NH2xVZgyQDR\|NEG0OS=>
DU145	MWLGeY5kfGmxbjDBd5NigQ>?			NYP6cFVCTE2VTx?=	NGC3[Y9KdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCGVUG0OUBk\WyuIIPjZZR1\XKrbnege4l1cCCLQ{WwJI9nKDFyIN88US=>	M1m0SFE5PDN2MUS1
KB3-1	NH[zT\|FEgXSxdH;4bYMhSXO\|YYm=		M{HCTlczKGh?	NGHJT3VFVVOR	M13YV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\3BvbnXnZZRqfmViS1KtN{0yKGOnbHzzJJdqfGhiSVO1NEBw\iB{LkOg{txO	M3jlRVE6Ozl5M{Ky
KBV1	M3rTb2N6fG:2b4jpZ{BCe3OjeR?=		MmGxO\|IhcA>?	MUDEUXNQ	M3TXTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\2y7Y3;wdo91\WmwLXX4dJJme3OrbnegT2JXOSClZXzsd{B4cXSqIFnDOVAhd2ZiND6xJO69VQ>?	MVWxPVM6PzN{Mh?=
A375	MWfDfZRwfG:6aXOgRZN{[Xl?		M2r1VVczKGh?	MVLEUXNQ	NXjDPIp{UUN3ME21MlQh\|ryP	NEK2RpgyQTZ3NESwPC=>
RS4-11	NXy2dJU{TnWwY4Tpc44hSXO\|YYm=		MoPVNkBp		MknlTY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFA6QSEQvF2=	MXSxPVY2PDRyOB?=
RS4-11	MkLMSpVv[3Srb36gRZN{[Xl?		MXeyJIg>		MlK1TY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzRizszN	Mnj5NVk3PTR2MEi=
Sf9	MX3LbY5ie2ViQYPzZZk>		MoPLN\|AhdWmw		M3HYU2lvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDWSWdHWiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvOTh3IN88US=>	NXzHUGsyOTl6NUSwOVE>
Ba/F3	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUm3NkBp		M{SzZWlEPTB;MT6yJO69VQ>?	NGfuWW8zODFzN{CwOC=>
BaPTC2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\pZ5U4OiCq		MVHJR\|UxRTBwMkKg{txO	MlrlNlAyOTdyMES=
Sf9	NHSxSldHfW6ldHnvckBCe3OjeR?=		MUSxJIg>	NEXkR3pFVVOR	MnK1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR\|UxKG:oIEGuN{DPxE1?	MVeyNFEyPzByNB?=
H4	NIn4e2VEgXSxdH;4bYMhSXO\|YYm=	MX:xNEDPxE1?			NX;lZnRxXG:6aXPpeJkhcW5iaIXtZY4hUDRiY3XscJM>	NHLad3AzODN3MEiwOi=>
SF-539	NFzDdo5McW6jc3WgRZN{[Xl?	M{XEd\|M{OyEQvF2=	M17qNlYxKG2rbh?=	M{OwbGROW09?	MWjJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEGyMlIh\|ryP	MmjBNlA1ODN5MEC=
U251	M1fQTWtqdmG\|ZTDBd5NigQ>?	NGjvcWQ{OzNizszN	M{P5N\|YxKG2rbh?=	MUjEUXNQ	NVS1UGJMUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?=	NY\5fmlZOjB2MEO3NFA>
A431	NUjTblJ2U2mwYYPlJGF{e2G7				M4G4WmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOTJwMjFOwG0>	NUmwZnZuOjB3NUiwO\|I>
A431	MX3LbY5ie2ViQYPzZZk>				NHnqVZlKdmirYnn0bY9vKG:oIG\FS2ZTOiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFE5NjlizszN	M{T2bVIxPTV6MEey
HepG2	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUfqOlh3PzJiaB?=		MoC3TWM2OD1\|LkixJO69VQ>?	M1fXV\|IxPTdyNUK2
Kasumi-1	M1zFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rxVlczKGh?		NGf3fVBKSzVyPUCuNFE3KM7:TR?=	NGnDXI0zODV5MEWyOi=>
RS4-11	NG[1Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVv0WFMyPzJiaB?=		NUO1fFdVUUN3ME2xJO69VQ>?	MYGyNFU4ODV{Nh?=
THP1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUi3NkBp		MYnJR\|UxRTBwNTFOwG0>	MnrrNlA2PzB3Mk[=
Kasumi-1	NFTZTG5HfW6ldHnvckBCe3OjeR?=				M3nwSmlvcGmkaYTpc44hd2ZiYz3LbZQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOTVizszN	MYKyNFg{OzB\|OR?=
A549	NV7IVFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkLMNVYhcA>?		M33lcmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIO=	MYKyNVQ2ODR4Mx?=
HL60	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTxRmluOTZiaB?=		MmjpRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\Wyucx?=	M4rZVFIyPDVyNE[z
HUVEC	M2jBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXexOkBp		MljNTY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iB{Lke1JO69VQ>?	MlHNNlE1PTB2NkO=
HUVEC	NIHxTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWfF[oFTOTZiaB?=		NV3NUGl{UW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?=	M1vTcFIyPDVyNE[z
IM9	NIf6WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3ruPVE3KGh?		NV\kPHlOSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz	MknCNlE1PTB2NkO=
K562	MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnHENVYhcA>?		MmDMRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\Wyucx?=	NYTWXVRHOjF2NUC0OlM>
MDA-MB-231	NWHWU\|NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3qx[VE3KGh?		M3vvfGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN?	M1vhflIyPDVyNE[z
H460	M37lU2N6fG:2b4jpZ{BCe3OjeR?=		NGHTfm84OiCq		M37ydWlEPTB;Mj63JO69VQ>?	M{TjUlIyPjJzOEiw
SMMC7721	MW\DfZRwfG:6aXOgRZN{[Xl?		MlPVO\|IhcA>?		M3jiXmlEPTB;Nj60O{DPxE1?	Mk\MNlE3OjF6OEC=
WI38	NUjYVYJnS3m2b4TvfIlkKEG\|c3H5		MYO3NkBp		NETyb4pKSzVyPUiuOVYh\|ryP	NHP4b3EzOTZ{MUi4NC=>
HEK293	NV\NOZl[U2mwYYPlJGF{e2G7	MlPGNVAxKG6P	NXfXbYhVOSCq		MYfkc4V{KG6xdDDpcohq[mm2IG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIIT5do9{cW6nIEGxO\|UhemW\|aXT1[UBwdiCYRVfGVlIh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsdy=>	MlHZNlE5QDV{OEe=
HUVEC	MWjGeY5kfGmxbjDBd5NigQ>?	M{\TflEh\|ryP	NEfvTXYzPCCq		NIHq[2lCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCYRVfGMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25?	MnOwNlE6PjN\|MEW=
HUVEC	MV\GeY5kfGmxbjDBd5NigQ>?	Ml64NUDPxE1?	NV7l[VhmOSCq		NGDXRYFKdmirYnn0bY9vKG:oIFXST{BxcG:\|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDpckBXTUeILYP0bY12dGG2ZXSgTHVXTUN?	M2fLSVIyQTZ\|M{C1
HUVEC	M2DMS2Z2dmO2aX;uJGF{e2G7	NFHRbIoyKM7:TR?=	MoGxNUBp		M1:4d2lvcGmkaYTpc44hd2ZiZV7PV{BxcG:\|cHjvdplt[XSrb36gZZQhW2W{LUGxO\|IhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD	NGLPOWUzOTl4M{OwOS=>
HUVEC	M1jJR2tqdmG\|ZTDBd5NigQ>?	MlvENUDPxE1?	MUmxJIg>		MVjJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:\|cHjvdplt[XSrb36gZZQhfHm{LUGxO\|UhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD	NWDIN\|M5OjF7NkOzNFU>
HUVEC	M37uZ2Z2dmO2aX;uJGF{e2G7	MYOxJO69VQ>?	NITKTmYyKGh?		MYLkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:\|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO=	MkfwNlE6PjN\|MEW=
HL60	NFjzZlJEgXSxdH;4bYMhSXO\|YYm=	NYr2XIhSPTBizszN	NYrpZYxiPDhiaB?=	MnvNSG1UVw>?	M2LmZ2lEPTB;MUWuOUDPxE1?	M4nUeVIzODF7MUi4
K562	NIXV[4NEgXSxdH;4bYMhSXO\|YYm=	NHnmSHo2OCEQvF2=	NWLocVR{PDhiaB?=	NULxfFZZTE2VTx?=	MofFTWM2OD1{MT65JO69VQ>?	NUH3XHV{OjJyMUmxPFg>
PC3	M4K0cmN6fG:2b4jpZ{BCe3OjeR?=	NVnTU4Y1PTBizszN	M3LlPVQ5KGh?	NIHjb\|lFVVOR	M325ZmlEPTB;MkWuNUDPxE1?	M3f1VFIzODF7MUi4
SF-539	MYXLbY5ie2ViQYPzZZk>	MWizN\|Mh\|ryP	MVO2NEBucW5?		MkTtTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFidInyc5NqdmVia3nuZZNmKGGldHn2bZR6KGmwIGDES2YuSkJvc4TpcZVt[XSnZDDoeY1idiCVRj21N\|kh[2WubIOge4l1cCCLQ{WwJI9nKDF{LkKg{txO	Mn;wNlIzODR5NEG=
HAEC	NGL2W4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIW3TIEyODBizszN	MonYO\|IhcA>?		M1nvbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFHFR{Bk\WyuczDlfJBz\XO\|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjFizszN	NGXYVlEzOjR2NE[3PS=>
HT-29	NFTFVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fsd\|ExOCEQvF2=	NFLPXIU4OiCq		MnTQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDlfJBz\XO\|aX7nJHZGT0[UIIfpeIghUUN3MDDv[kAxNjN\|IN88US=>	MXeyNlQ1PDZ5OR?=
MV4-11	Mn75R5l1d3SxeHnjJGF{e2G7		MVm3NkBp		Mn3TTWM2OD1yLkCwN{DPxE1?	NIXET3YzOjR3MkWxPC=>
HepG2	NYLXR3EzS3m2b4TvfIlkKEG\|c3H5		Mo\MOFghcA>?		Mm\ITWM2OD1zMz6yOEDPxE1?	MXGyNlQ5OzZyOB?=
PC9	MofuR5l1d3SxeHnjJGF{e2G7		NFvZU2Y1QCCq		Mn;0TWM2OD1zMD65O{DPxE1?	M4DKblIzPDh\|NkC4
CAKI-1	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOxNFAh\|ryP	Mn3KOFghcA>?	MkXjSG1UVw>?	M3;ITmdKPTB;MD62N{DPxE1?	NUXLXmVuOjJ3NkC2Nlc>
EKVX	NXHGZnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\NNVAxKM7:TR?=	Mn\zOFghcA>?	M1PiRWROW09?	MX7HTVUxRTdwOTFOwG0>	NYjWSm9nOjJ3NkC2Nlc>
MCF7	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\3XYNqOTByIN88US=>	M4\OeFQ5KGh?	NGnodW9FVVOR	NXvKeod[T0l3MU2yJO69VQ>?	MnzWNlI2PjB4Mke=
MDA-MB-435	NGKy[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3L4OlExOCEQvF2=	MmryOFghcA>?	MnrxSG1UVw>?	M2[wU2dKPTJ;MjFOwG0>	M2\aelIzPTZyNkK3
OVCAR3	NHfiTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYOwbFBzOTByIN88US=>	M13NcVQ5KGh?	M2T1SmROW09?	NIjaN\|BIUTV\|PUOuNkDPxE1?	NFy4OlMzOjV4ME[yOy=>
SNB19	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInaUnMyODBizszN	MoLtOFghcA>?	MX7EUXNQ	M{TDS2dKPTR;MUCg{txO	NXHoeGhEOjJ3NkC2Nlc>
SW620	NUXvR3BYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXizbXBMOTByIN88US=>	MUe0PEBp	MmjySG1UVw>?	M4XpdmdKPTV;MT6zJO69VQ>?	NGDBN4ozOjV4ME[yOy=>
TK10	NIfwXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvsN4xXOTByIN88US=>	MlzGOFghcA>?	M1jYeGROW09?	Mki3S2k2Pj14LkOg{txO	NYDKS2VbOjJ3NkC2Nlc>
UACC257	NWD1Xo1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnX2NVAxKM7:TR?=	NVnNfog3PDhiaB?=	MkPsSG1UVw>?	MX3HTVU4RTRizszN	MnP3NlI2PjB4Mke=
HAEC	MonwR5l1d3SxeHnjJGF{e2G7	Ml;INVAxKM7:TR?=	NInYOmY4OiCq	Mn7USG1UVw>?	NGrPcJlEgXSxdH;4bYNqfHliYXfhbY5{fCCYRVfGVkBmgHC{ZYPzbY5oKEiDRVOge4l1cCCLQ{WwJI9nKDBwMTFOwG0>	NHjvWY8zOzF\|MUW0NS=>
HT-29	NIjpcVlEgXSxdH;4bYMhSXO\|YYm=	MkPrNVAxKM7:TR?=	NGryTHM4OiCq	M1TFWWROW09?	NYnOd5VES3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCqdX3hckBJXC1{OTDj[YxteyC5aYToJGlEPTBib3[gNE4{OyEQvF2=	M3zGRVI{OTNzNUSx
HCT116	M{XrbGZ2dmO2aX;uJGF{e2G7		NWnsXZhyOjRiaB?=	NYDuXXpQTE2VTx?=	MlHpRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygcYloemG2aX;u	NHnzR\|UzOzF3M{KwNC=>
HUVEC	Mlu3SpVv[3Srb36gRZN{[Xl?	NWS2XnV4OiEQvF2=	NUPNTWhSOThiaB?=	NH60PIZFVVOR	MWrBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGS3NidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fWKnIH\vdo1ifGmxbh?=	Mn7WNlMyPTN{MEC=
ACHN	M1\obmN6fG:2b4jpZ{BCe3OjeR?=		NXXlN\|J7PiCm		M3T1cGlEPTB;Mj61JO69VQ>?	MV6yN\|M3ODFyNB?=
A498	M4e0TGN6fG:2b4jpZ{BCe3OjeR?=	Mn3SNVAxKM7:TR?=	M3K0bVczKGh?	MVvEUXNQ	MWTJR\|UxRTRwMzFOwG0>	NV7mc2lIOjN2OEm2NlY>
HUVEC	NIGxeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkWxN{DPxE1?	Mnz5NlQhcA>?	MX\EUXNQ	NVLydWFNSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhfHWkZTDmc5Ju[XSrb36ge4l1cCCHQ{WwJI9nKDBwNkS1JO69VQ>?	NYK0botxOjN3OEO5NVE>
HUVEC	MnPkT4lv[XOnIFHzd4F6	MkX5NlAxKM7:TR?=		NFWwZoVFVVOR	NGP6RmtKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD	NIrPbXIzOzV6M{mxNS=>
HUVEC	M174WGtqdmG\|ZTDBd5NigQ>?	NF;mVXMzODBizszN		NFrzbGZFVVOR	M2\G[GlvcGmkaYTpc44hd2ZiVlXHSnIyKHCqb4PwbI9zgWyjdHnvckBqdiCpcn;3eIgh\mGldH;yMZN1cW23bHH0[YQhUFWYRVO=	NYDuSIVpOjN3OEO5NVE>
A549	NYDsVYJiS3m2b4TvfIlkKEG\|c3H5		Mn:1O\|IhcA>?	NVXITY5uTE2VTx?=	M4S2W2lEPTB;Mj60OEDPxE1?	MXWyN\|YxOjR2MR?=
HCT116	MnHZR5l1d3SxeHnjJGF{e2G7		MYW3NkBp	MVzEUXNQ	MXLJR\|UxRTRwN{Gg{txO	MnfBNlM3ODJ2NEG=
MCF7	NIXo[3BEgXSxdH;4bYMhSXO\|YYm=		NXLxO2dTPzJiaB?=	M3vCXWROW09?	MWrJR\|UxRTZwMkmg{txO	MUiyN\|YxOjR2MR?=
BGC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkjFO\|IhcA>?	NYLpdJlwTE2VTx?=	NWHyOoRbUUN3ME20Mlc5KM7:TR?=	M1O3e\|I{QTl7MESw
BxPC3	NGrxTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17NXVczKGh?	NEC5NWdFVVOR	MnHITWM2OD1\|Lk[zJO69VQ>?	MmjaNlM6QTlyNEC=
HT-29	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\MXFczKGh?	NHW1UI5FVVOR	MkSxTWM2OD1zLkS3JO69VQ>?	MVSyN\|k6QTB2MB?=
T24	NUnqZmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV23NkBp	NG\QNFFFVVOR	MUfJR\|UxRTJwNESg{txO	NHHiZVczOzl7OUC0NC=>
4T1	MmT0R5l1d3SxeHnjJGF{e2G7		MmDLO\|IhcA>?	NFXHUVdFVVOR	MlL1TWM2OD1yLkCxOkDPxE1?	Mke4NlQ5QTB4NUK=
MCF7	MWDDfZRwfG:6aXOgRZN{[Xl?		MVi3NkBp	NE\GXXhFVVOR	NV\YVWVGUUN3ME2wMlAzPzFizszN	MXGyOFg6ODZ3Mh?=
MCF7	MXvDfZRwfG:6aXOgRZN{[Xl?		MkTyO\|IhcA>?	MUPEUXNQ	NX\hN29qUUN3ME2wMlAzQTNizszN	NV;kfFBwOjR6OUC2OVI>
MDA-MB-231	MmHrR5l1d3SxeHnjJGF{e2G7		MUm3NkBp	M4q0ZWROW09?	MmS1TWM2OD1yLkCyNlMh\|ryP	NHqy[IQzPDh7ME[1Ni=>
MDA-MB-435	NH3EZXBEgXSxdH;4bYMhSXO\|YYm=		MljZO\|IhcA>?	NV3CfHdrTE2VTx?=	MVTJR\|UxRTBwMEC5O{DPxE1?	M4TUcVI1QDlyNkWy
MDA-MB-468	M1qzPWN6fG:2b4jpZ{BCe3OjeR?=		NFzBOYU4OiCq	MmrSSG1UVw>?	MVHJR\|UxRTBwMEC2NUDPxE1?	M1\uXFI1QDlyNkWy
A431	M{jGfmtqdmG\|ZTDBd5NigQ>?	NYKzbm9IOTBizszN	NHnNWJEyKGh?	NWDmNIV[TE2VTx?=	NXfQ[VFGUW6qaXLpeIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlE4OjFizszN	MXOyOFg6ODZ3Mh?=
SH-SY5Y	M2n1N2tqdmG\|ZTDBd5NigQ>?	NVuzT5lQOTBizszN	M2jXRVEhcA>?	M1vhN2ROW09?	MYLJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC5aYToJGlEPTBib3[gNE4xQDNzIN88US=>	NYWxPI1OOjR6OUC2OVI>
U251	NH[z[llMcW6jc3WgRZN{[Xl?	MWixNEDPxE1?	NHLsWXYyKGh?	NV\y[HhJTE2VTx?=	MWTJcohq[mm2aX;uJI9nKF[HR1\SNkB4cXSqIFnDOVAhd2ZiMD6wNVg6KM7:TR?=	Ml;sNlQ5QTB4NUK=
Bel7402	NUDhdmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1XoWVczKGh?	NF;McnlFVVOR	MXzJR\|UxRTJwNkeg{txO	MWmyOFkxPDl4MR?=
HK2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfvWZpmPzJiaB?=	NWHv[3dYTE2VTx?=	M{LXeWlEPTB;NT64OUDPxE1?	NEnIOI4zPDlyNEm2NS=>
LO2	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3LrdFczKGh?	MYHEUXNQ	NGX3ZY1KSzVyPUG5Mlk{KM7:TR?=	NVqwUYxXOjR7MES5OlE>
MV4-11	M1mz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUf3dWd7PDhiaB?=	NXjpXng6TE2VTx?=	M2fIemlEPTB;MD6wNFMh\|ryP	MlTlNlQ6ODR7NkG=
NCI-H3122	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHxO\|IhcA>?	MlTBSG1UVw>?	MVnJR\|UxRTBwOEOg{txO	NHzmZ3EzPDlyNEm2NS=>
NCI-H460	M2jhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4TvZlczKGh?	NWXie41kTE2VTx?=	NU\I[GZkUUN3ME20MlMyKM7:TR?=	M13MWFI1QTB2OU[x
NCI-H526	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUK3NkBp	MmD4SG1UVw>?	NFzzPZRKSzVyPUGuNFEh\|ryP	NWnmeHVHOjR7MES5OlE>
TT	M4HFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3Hz[VczKGh?	M4P4VGROW09?	MXfJR\|UxRTBwMESg{txO	MkHRNlQ6ODR7NkG=
EoL-1-cell	M2Dr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL6TWVMUUN3ME2xMlY1KHCP	M2ftcHNCVkeHUh?=
MV-4-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;aTWM2OD1{N{KgdG0>	MnT3V2FPT0WU
NOS-1	M2OxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvuPZhKSzVyPUG1MlMhdk1?	M1LpfnNCVkeHUh?=
CGTH-W-1	NVjJNFdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTNyLkm0JI5O	NEf5[49USU6JRWK=
MONO-MAC-6	M3z5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LnbWlEPTB;M{OuPEBvVQ>?	NXLaXoltW0GQR1XS
ALL-PO	M{KxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTd7Lki5JI5O	MX;TRW5ITVJ?
NKM-1	M2\ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfYOWNKSzVyPUm4MlUzKG6P	MojyV2FPT0WU
KM12	NV;SOZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nLSGlEPTB;M{WwMlE1KG6P	NUnjR3FRW0GQR1XS
TE-15	M33hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEToPYxKSzVyPUWwO{43OSCwTR?=	NV\MNoVtW0GQR1XS
697	M{XEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLhTWM2OD14MUSuNlUhdk1?	M2\mPXNCVkeHUh?=
MOLT-16	NXz5eVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnhTWM2OD14M{GuN\|Ihdk1?	NV3yTZlvW0GQR1XS
GB-1	NH;hR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIix[4NKSzVyPUexNE4zOyCwTR?=	NHjPdW9USU6JRWK=
TE-12	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRThyND61OUBvVQ>?	NHLkfJpUSU6JRWK=
ES6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTl6MT6wOkBvVQ>?	MWfTRW5ITVJ?
LC-2-ad	NXXkbmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHCTWM2OD1zLkGxOFA4KM7:TR?=	NFjMTHlUSU6JRWK=
BL-70	NX3JfZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;KdmxKSzVyPUGuNVE5PDZizszN	NHvTb\|lUSU6JRWK=
ETK-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7jS5M2UUN3ME2xMlI5PThizszN	MUfTRW5ITVJ?
A4-Fuk	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{P1bGlEPTB;MT6zOFE1OSEQvF2=	NHzYSohUSU6JRWK=
OCI-AML2	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mke2TWM2OD1zLkO2PFUyKM7:TR?=	Moi3V2FPT0WU
SIG-M5	NWnYT3pLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7WTWM2OD1zLkO3NFA6KM7:TR?=	MVzTRW5ITVJ?
NCI-SNU-16	NVrUe\|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF20WpdKSzVyPUGuOFY1QDZizszN	M1;xNnNCVkeHUh?=
PSN1	M4XWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGT2RYhKSzVyPUGuOVA3PzZizszN	NInWdmpUSU6JRWK=
SR	NHPDeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlX6TWM2OD1zLkW0OVczKM7:TR?=	NYi1V4hJW0GQR1XS
A3-KAW	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rTRmlEPTB;MT62NlU1PiEQvF2=	NH;uVW1USU6JRWK=
KS-1	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\IbVVrUUN3ME2xMlY6OjR5IN88US=>	MnzPV2FPT0WU
CTV-1	NEfjTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPlO3BGUUN3ME2xMlczPzVzIN88US=>	M125cnNCVkeHUh?=
LB1047-RCC	NEfDZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTFwOEG2NlQh\|ryP	MoP2V2FPT0WU
EMG-01	NVnQboxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fNU2lEPTB;MT64N\|U3OyEQvF2=	NWT4dXRGW0GQR1XS
TE-11	NH\uXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K3dGlEPTB;MT64N\|k5PSEQvF2=	M3TTenNCVkeHUh?=
CMK	NXHrbJNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzydWVqUUN3ME2xMlk2PTF5IN88US=>	NEXjcHpUSU6JRWK=
NB1	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TQTWlEPTB;MT65OlEyPyEQvF2=	M1mx[XNCVkeHUh?=
HAL-01	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkW1TWM2OD1{LkC1PVQ3KM7:TR?=	NIm5UGZUSU6JRWK=
DEL	NIjvOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJwMEi0PFIh\|ryP	NHjaS\|FUSU6JRWK=
RL95-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjCb4NKSzVyPUKuNVEyOzdizszN	NYXmfGhOW0GQR1XS
KARPAS-299	M4nROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmSzTWM2OD1{LkGxN\|E{KM7:TR?=	MUXTRW5ITVJ?
EW-16	NUPRNWltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LVOGlEPTB;Mj6xN\|UxQCEQvF2=	NGTSR4JUSU6JRWK=
RS4-11	M{T2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJwMUe5NlQh\|ryP	M3jzNnNCVkeHUh?=
BB30-HNC	M3TWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37INGlEPTB;Mj6yNlM4PSEQvF2=	Mo\yV2FPT0WU
DOHH-2	NGDLXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJwM{O0N\|Eh\|ryP	M2fGNHNCVkeHUh?=
RPMI-8402	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjRfpRGUUN3ME2yMlM{PjF6IN88US=>	MX7TRW5ITVJ?
BV-173	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJwM{O2OkDPxE1?	MlzjV2FPT0WU
TE-10	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LWWWlEPTB;Mj6zOFM5PCEQvF2=	NF21N5RUSU6JRWK=
TE-8	NXjxSGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT2VlZ{UUN3ME2yMlM4ODN6IN88US=>	MXTTRW5ITVJ?
K052	NIHsSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4SzfWlEPTB;Mj60NFIxOiEQvF2=	MWnTRW5ITVJ?
KARPAS-45	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HhT2lEPTB;Mj60PVQ1PiEQvF2=	MnPxV2FPT0WU
SK-NEP-1	NFjTcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3uRXlKSzVyPUKuOlAzOzdizszN	NUCwOIxlW0GQR1XS
KGN	NEWySnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfMOWdKSzVyPUKuOlA{OzlizszN	MkiyV2FPT0WU
ML-2	M4KxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HKd2lEPTB;Mj62N\|UyOiEQvF2=	NIPZcnpUSU6JRWK=
LAMA-84	NEHRRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXryVnJQUUN3ME2yMlY6PTR3IN88US=>	MoD0V2FPT0WU
LXF-289	M3Li[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HPXWlEPTB;Mj63Nlk5QSEQvF2=	M4\qb3NCVkeHUh?=
A101D	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYSzd2dwUUN3ME2yMlc5OzB2IN88US=>	NUTKfJZ7W0GQR1XS
KY821	NYDmRo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEm2d3NKSzVyPUKuO\|k4PThizszN	M3vEfXNCVkeHUh?=
ES4	NULJc5QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWWye2dlUUN3ME2yMlgxPjJ6IN88US=>	M3jHZXNCVkeHUh?=
SCC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjORXVbUUN3ME2yMlgzQDlzIN88US=>	NYTqfJBPW0GQR1XS
NALM-6	NFnWfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LnNmlEPTB;Mj65NFQ4OyEQvF2=	NWnnXmRsW0GQR1XS
BL-41	M1yyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnMOmlKSzVyPUKuPVEzOjJizszN	M3roPXNCVkeHUh?=
OPM-2	NHLXSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGj5ZlNKSzVyPUOuNFU6PTRizszN	M3nQb3NCVkeHUh?=
SF126	NGDhcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XORmlEPTB;Mz6wOlE6QCEQvF2=	Mln3V2FPT0WU
BE-13	M{\nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDHTGFKSzVyPUOuNlMyOTFizszN	MlvOV2FPT0WU
SF268	NX\ob\|BQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\XWGZKSzVyPUOuN\|I5PjlizszN	NEnnPJpUSU6JRWK=
MOLT-4	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTNwM{m4N\|gh\|ryP	MXrTRW5ITVJ?
PF-382	MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMWHM4UUN3ME2zMlQ1PTdizszN	NYO4WVd4W0GQR1XS
HEL	NEDHU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTNwNEiwNFUh\|ryP	MnL1V2FPT0WU
RPMI-6666	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fnN2lEPTB;Mz61OFE4OSEQvF2=	NGXobJBUSU6JRWK=
QIMR-WIL	M17LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIToZ\|JKSzVyPUOuOlM{QTFizszN	MnPQV2FPT0WU
ATN-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvRT3JZUUN3ME2zMlY4OTF2IN88US=>	Mn;2V2FPT0WU
BB49-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\OTWM2OD1\|LkewOVA5KM7:TR?=	NFnmWm9USU6JRWK=
HCE-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTNwN{i2OFIh\|ryP	MYHTRW5ITVJ?
SK-LMS-1	M3jicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwOEOzN\|gh\|ryP	NF;DN29USU6JRWK=
MS-1	NEfJcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TkcGlEPTB;Mz64N\|c4QCEQvF2=	NVy3fWRSW0GQR1XS
JAR	NInnTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTNwOUi4N\|Ih\|ryP	MojmV2FPT0WU
KE-37	NHz0UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXiTWM2OD12LkC2NVU5KM7:TR?=	NX3YUoxwW0GQR1XS
LB996-RCC	M1O0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVKxO4VOUUN3ME20MlEzOTZ6IN88US=>	M{TUenNCVkeHUh?=
HH	NFP5RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjkTWM2OD12LkKwPVE1KM7:TR?=	M3HrSnNCVkeHUh?=
HL-60	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTpTmw4UUN3ME20MlIyODZ3IN88US=>	MWfTRW5ITVJ?
HOP-62	NV;SNZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnre4ExUUN3ME20MlM{PTJizszN	NWG1U2VFW0GQR1XS
NOMO-1	NEOyWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HPNWlEPTB;ND6zN\|Y6QSEQvF2=	MnzLV2FPT0WU
DU-4475	NWnFfVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUj4fo55UUN3ME20MlM3PzJ7IN88US=>	M3PWe3NCVkeHUh?=
LC4-1	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr2Rm5FUUN3ME20MlM5ODdizszN	M3O0dnNCVkeHUh?=
MC116	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTRwNEOwPFEh\|ryP	MojMV2FPT0WU
SW982	NFzMeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDCW29KSzVyPUSuOVU{ODdizszN	NVG2TXN5W0GQR1XS
SK-N-DZ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGr2UVlKSzVyPUSuOlcxQTlizszN	NGHW[FFUSU6JRWK=
EW-1	NYXFNWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPDZoRKSzVyPUSuOlc6OTFizszN	MkDuV2FPT0WU
SU-DHL-1	NU\pNIhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjVTWM2OD12LkiwNVc1KM7:TR?=	M1LPVHNCVkeHUh?=
L-363	NEDFeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\IbJdkUUN3ME20MlgxPjJzIN88US=>	NFHBUVJUSU6JRWK=
OS-RC-2	NV\VXIRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTRwOEezNUDPxE1?	NH;BfYlUSU6JRWK=
HD-MY-Z	NXm1U29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrtR3Y4UUN3ME21MlE4OzBzIN88US=>	M3nWO3NCVkeHUh?=
MHH-PREB-1	NIC2OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvFVohCUUN3ME21MlMzOzF{IN88US=>	MUTTRW5ITVJ?
HC-1	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfFXIhKSzVyPUWuOFMzQTFizszN	NF7kR\|FUSU6JRWK=
SK-MM-2	NU\jfVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vRSWlEPTB;NT60O\|gzKM7:TR?=	M4DSW3NCVkeHUh?=
SH-4	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mly5TWM2OD13LkS4N\|ch\|ryP	Mn7FV2FPT0WU
MHH-CALL-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1npemlEPTB;NT63OlcyQSEQvF2=	NHLBWHFUSU6JRWK=
KG-1	NXHzNoh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTZwMEK4O\|gh\|ryP	MYjTRW5ITVJ?
J-RT3-T3-5	NVTYTo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTZwMEe5NFkh\|ryP	M4fvdnNCVkeHUh?=
MMAC-SF	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\UXWlEPTB;Nj6xNFk1QSEQvF2=	Mnf3V2FPT0WU
IST-SL2	NH;QeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7lTWM2OD14LkGyOVE6KM7:TR?=	MUXTRW5ITVJ?
SW954	NYP3OVA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTGZ5pFUUN3ME22MlI4PTF5IN88US=>	NWm5bXZnW0GQR1XS
HDLM-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;CVmlEPTB;Nj6zNlExQSEQvF2=	MnrGV2FPT0WU
ST486	NF3Xb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;qTWM2OD14LkO0O\|Eh\|ryP	MnS4V2FPT0WU
DG-75	NHfQN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13JUmlEPTB;Nj60N\|A3QSEQvF2=	NF3wNJZUSU6JRWK=
EW-3	NX\OZ4VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPNTWM2OD14LkSzNlA4KM7:TR?=	NWPpT3lTW0GQR1XS
8-MG-BA	NVv0cWlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTZwNUG1NFch\|ryP	M2LHd3NCVkeHUh?=
GT3TKB	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XIeGlEPTB;Nj62NFc3OyEQvF2=	M3zrV3NCVkeHUh?=
KU812	M13iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTZwNkm0NkDPxE1?	NH\XUHFUSU6JRWK=
CESS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrEVoFTUUN3ME23MlExPDN6IN88US=>	NXTDS5dkW0GQR1XS
BC-1	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rNe2lEPTB;Nz6yOFgyOiEQvF2=	NEOwOY1USU6JRWK=
MZ1-PC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLuO3RKSzVyPUeuN\|A{QDlizszN	MXjTRW5ITVJ?
NCI-H82	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moi0TWM2OD15LkO3PFUh\|ryP	NYfyNmM4W0GQR1XS
NCI-H1355	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXU[W44UUN3ME23MlQ2QDB2IN88US=>	M2j1[HNCVkeHUh?=
RPMI-8226	NWDSSHhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\XSWlEPTB;Nz61NFc{QSEQvF2=	MXjTRW5ITVJ?
ARH-77	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoraTWM2OD15LkWzOVk4KM7:TR?=	NUf4ToVYW0GQR1XS
MN-60	M2HlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELTT2dKSzVyPUeuOVQxQDhizszN	MXzTRW5ITVJ?
IMR-5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTdyNUS4O\|Yh\|ryP	MnK2V2FPT0WU
KARPAS-422	NFHOSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnewTWM2OD15LkW3NlA3KM7:TR?=	MmrzV2FPT0WU
CA46	NUfsSIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTdwNUiwNVIh\|ryP	Mn\lV2FPT0WU
SJSA-1	MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTdwNk[wOlEh\|ryP	NEixb4JUSU6JRWK=
no-11	NFXp[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jqO2lEPTB;Nz63O\|U2PyEQvF2=	NXPveWc{W0GQR1XS
IST-SL1	M2HFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRThwMEK0NVch\|ryP	MXHTRW5ITVJ?
NCI-H209	NUnhVlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRThwMUG2OVIh\|ryP	M2XNd3NCVkeHUh?=
TALL-1	MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17q[mlEPTB;OD6xPFM5PCEQvF2=	MkDlV2FPT0WU
KMOE-2	M1;rcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRThwMUm0NkDPxE1?	NF\0SmJUSU6JRWK=
HCC1599	NXy5bYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7NSGNmUUN3ME24MlE6QTh5IN88US=>	NGG3TVZUSU6JRWK=
CI-1	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4H3dWlEPTB;OD6yNFQyOSEQvF2=	NGLh[ndUSU6JRWK=
NCI-H1304	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIOxb\|NKSzVyPUiuNlA3PjFizszN	MV3TRW5ITVJ?
Daudi	NInLTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f2bWlEPTB;OD6yN\|U1PiEQvF2=	M17rUXNCVkeHUh?=
CPC-N	M4jzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjTTIpKSzVyPUiuNlkyQTlizszN	MV\TRW5ITVJ?
MC-CAR	M2fhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXOTWM2OD16LkOzOVgh\|ryP	NHvhc4ZUSU6JRWK=
SW872	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LBcGlEPTB;OD6zOFc2QCEQvF2=	MlLqV2FPT0WU
OVCAR-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2e1ZmlEPTB;OD61NFM2OSEQvF2=	NXHtNnFWW0GQR1XS
OCUB-M	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRThwNU[1NFgh\|ryP	NHTPV\|RUSU6JRWK=
SK-PN-DW	NUH6So9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrxOpdKSzVyPUiuOlA6QDVizszN	M3j4[HNCVkeHUh?=
NCCIT	NHLi[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfVV5ZTUUN3ME24MlcyPzR3IN88US=>	MkKwV2FPT0WU
NCI-H1648	NWjrSlF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ToPGlEPTB;OT6xN\|g{PCEQvF2=	MlHuV2FPT0WU
COR-L279	NX3DU3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XINWlEPTB;OT6zPVA6KM7:TR?=	NFTSc5lUSU6JRWK=
LS-123	NYnQ[YV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLhTWM2OD17Lk[4NVYyKM7:TR?=	MVTTRW5ITVJ?
LP-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrXUZJKSzVyPUmuO\|gxQDNizszN	M2fXUHNCVkeHUh?=
NB13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljZTWM2OD17Lke5PVk1KM7:TR?=	MV3TRW5ITVJ?
ONS-76	NUTPSnNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7xTWM2OD17LkixNFE3KM7:TR?=	M1vuW3NCVkeHUh?=
VA-ES-BJ	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTlwOUm5N\|Mh\|ryP	NYLNOnhDW0GQR1XS
GR-ST	NWW0bXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfFTWM2OD1zMD6yNlA4KM7:TR?=	MVLTRW5ITVJ?
ES1	NWLmR4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLrVWNMUUN3ME2xNE4zQTh2IN88US=>	NWPOSYx6W0GQR1XS
NB14	NV\Yfno2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TxfmlEPTB;MUCuPVI4PyEQvF2=	NVy2e5pVW0GQR1XS
Ramos-2G6-4C10	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XxTGlEPTB;MUGuNlY2KM7:TR?=	MlHzV2FPT0WU
RXF393	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4f4TGlEPTB;MUGuOFg{PCEQvF2=	NHnzdFlUSU6JRWK=
NCI-H2107	M1fGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\Vd5JmUUN3ME2xNU42QTh2IN88US=>	NGnvfJpUSU6JRWK=
K562	NF;LNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPlNIFKSzVyPUGxMlg4ODJizszN	MXnTRW5ITVJ?
LOUCY	NXvtNWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFzLkm4O\|Uh\|ryP	M3y4fHNCVkeHUh?=
TGBC1TKB	M{HIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTF{LkCwNkDPxE1?	MWrTRW5ITVJ?
COLO-320-HSR	NF23[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\VOXNKSzVyPUGyMlE2PjVizszN	MXnTRW5ITVJ?
K5	NYq0TolDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rZNWlEPTB;MUKuNlk5PSEQvF2=	MXzTRW5ITVJ?
BC-3	NX75TFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX0TWM2OD1zMj60OlUyKM7:TR?=	NU\uNI1XW0GQR1XS
REH	NU\HcnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTF{Lk[0PVgh\|ryP	NVTXU40xW0GQR1XS
NEC8	M2HmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\qeZdKSzVyPUGyMlY5QDdizszN	M3:0WXNCVkeHUh?=
IST-MEL1	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTF{Lki2PVQh\|ryP	NH7NZ3JUSU6JRWK=
NCI-H128	NGP4fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF\|LkC3NlMh\|ryP	NX\yWVFKW0GQR1XS
NCI-H1694	M17VRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTF\|LkGxOFQh\|ryP	NGXXcFFUSU6JRWK=
TGW	M1;1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPlN4lPUUN3ME2xN{4{Ojd4IN88US=>	NH7OenhUSU6JRWK=
NCI-SNU-1	NXHLdINTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoewTWM2OD1zMz6zOFUh\|ryP	NYnN[HNZW0GQR1XS
IST-MES1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfPVYx3UUN3ME2xN{43PzJ7IN88US=>	M2rWdnNCVkeHUh?=
CTB-1	NYjlNHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnqZpFKSzVyPUGzMlczQTRizszN	MoXaV2FPT0WU
HUTU-80	NGDqSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn31TWM2OD1zMz63OVc{KM7:TR?=	M2HiXHNCVkeHUh?=
LAN-6	NFva[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvPU\|ZKSzVyPUG0MlI1PTdizszN	Mn60V2FPT0WU
KP-N-YS	NGLZNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTF2LkK4PVQh\|ryP	M1S0V3NCVkeHUh?=
CCRF-CEM	NHrWRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF2LkSxOlkh\|ryP	MUTTRW5ITVJ?
NCI-H1770	NXTW[3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULLdnE6UUN3ME2xOE42OzZ7IN88US=>	NVH4XHQxW0GQR1XS
MZ2-MEL	M{[zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX[4XXByUUN3ME2xOU4zOjVzIN88US=>	NH64R2NUSU6JRWK=
COR-L88	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfYTWM2OD1zNj6wNFEzKM7:TR?=	NV\od4pJW0GQR1XS
LOXIMVI	NGfMU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\1b4ZKSzVyPUG2MlI2PiEQvF2=	MW\TRW5ITVJ?
KALS-1	NXz5O5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjKUGQ1UUN3ME2xOk42QTNzIN88US=>	NEH1TndUSU6JRWK=
D-283MED	NYr6bZBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTF4Lki0PFkh\|ryP	MlLJV2FPT0WU
NCI-H719	M3nINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvWTWM2OD1zNj65NVYyKM7:TR?=	MVrTRW5ITVJ?
MLMA	NHnVWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDvOnBKSzVyPUG2Mlk6ODdizszN	NHq5[4dUSU6JRWK=
EVSA-T	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjxPXRKSzVyPUG3MlA1QDVizszN	MlPSV2FPT0WU
SK-N-FI	NUn4d3dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\ZVmlEPTB;MUeuOlkyOyEQvF2=	NEOwUJZUSU6JRWK=
NTERA-S-cl-D1	M3jCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF5Lki1O\|Ih\|ryP	Mn\pV2FPT0WU
NCI-H1882	NH62XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTF5Lkm4N\|Qh\|ryP	NXuzS2RzW0GQR1XS
A704	M2m3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfueHVKSzVyPUG3Mlk6ODRizszN	M3\4S3NCVkeHUh?=
L-428	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTQO2U3UUN3ME2xPE4xOTVzIN88US=>	M{TSSnNCVkeHUh?=
HCC1187	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnadWI5UUN3ME2xPE4xOTh5IN88US=>	NHv4NGtUSU6JRWK=
NCI-H1581	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF6LkC4OlYh\|ryP	M1zhNnNCVkeHUh?=
BB65-RCC	Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DR[WlEPTB;MUiuOFE3OiEQvF2=	MXfTRW5ITVJ?
EM-2	NXXpW3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\vbJRKSzVyPUG4MlU3PzJizszN	NFrj[npUSU6JRWK=
Raji	M1TKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{joNGlEPTB;MUmuPVU3PSEQvF2=	NGriTmdUSU6JRWK=
TE-1	NUDCOJNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKy[lZkUUN3ME2yNE41OTB2IN88US=>	M1jLTXNCVkeHUh?=
SW962	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJyLkSyPVMh\|ryP	MljEV2FPT0WU
MHH-NB-11	M3PsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITz[Y9KSzVyPUKwMlU2OjFizszN	M3zMfHNCVkeHUh?=
no-10	M3;Ibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPDVnNKSzVyPUKxMlAzPjRizszN	M3i0NHNCVkeHUh?=
GDM-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle4TWM2OD1{MT65OFE1KM7:TR?=	Mor2V2FPT0WU
KMS-12-PE	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXtTWM2OD1{Mj6yO\|Qh\|ryP	MUXTRW5ITVJ?
NCI-H510A	M{[0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HNW2lEPTB;MkSuNVI4QCEQvF2=	MVnTRW5ITVJ?
ES5	NW[1eJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTOTWM2OD1{ND63N\|Q6KM7:TR?=	NX;5OFNIW0GQR1XS
JiyoyeP-2003	M3W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjDXpBKSzVyPUK2MlI4PDJizszN	M2DlfnNCVkeHUh?=
NMC-G1	NULaPWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnLdI15UUN3ME2yO{4yQDJ{IN88US=>	NV;lO3VKW0GQR1XS
NCI-H446	M13lW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF33Z5dKSzVyPUK3MlQ6PDZizszN	NWXCPIJmW0GQR1XS
NB7	M3jZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnztTWM2OD1{Nz65NlI6KM7:TR?=	NEWxW3BUSU6JRWK=
A388	MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnnXWJKSzVyPUK4MlAxPzRizszN	NV3XO3ZEW0GQR1XS
JVM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LhU2lEPTB;MkiuNlg6QCEQvF2=	NEDsW4JUSU6JRWK=
HT-144	M3;XOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\jNnZKSzVyPUK4MlY6KM7:TR?=	MWrTRW5ITVJ?
NCI-H747	NGW5XpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmO0TWM2OD1{OD65NVk2KM7:TR?=	NH:1Z25USU6JRWK=
NCI-H1650	NEXwPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfFW25FUUN3ME2yPU4xOTd4IN88US=>	MVPTRW5ITVJ?
EB-3	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYi3bmxWUUN3ME2yPU42OzB7IN88US=>	MkWyV2FPT0WU
KLE	M3TOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnhfIU{UUN3ME2yPU43OTlizszN	NFvIZ\|hUSU6JRWK=
TK10	NHjGW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNyLkGyOkDPxE1?	NUjic405W0GQR1XS
COLO-668	M4q5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfZXJlKSzVyPUOwMlc6OiEQvF2=	MYDTRW5ITVJ?
NCI-H23	NH;JOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\iTWM2OD1\|MT6xNFY{KM7:TR?=	NE\qWWFUSU6JRWK=
GOTO	NFXaSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrPZ\|RsUUN3ME2zNU43ODh3IN88US=>	NWjyZXI{W0GQR1XS
MSTO-211H	NFj5TopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETmWYVKSzVyPUOxMlg3PzhizszN	NH7FNYxUSU6JRWK=
LB831-BLC	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjEV4ZKSzVyPUOyMlM5PDNizszN	MVzTRW5ITVJ?
SCH	M4HaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfWTWM2OD1\|Mj64OFg2KM7:TR?=	MWTTRW5ITVJ?
EHEB	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2X2N2lEPTB;M{SuNVE6OyEQvF2=	M1Xlc3NCVkeHUh?=
U-266	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN2LkK3PFEh\|ryP	MnzTV2FPT0WU
EW-11	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYG2endbUUN3ME2zOE41PzJ3IN88US=>	NFT0d2JUSU6JRWK=
TE-9	NFO0TXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHvU\|VKSzVyPUO3MlA1ODFizszN	M{TBd3NCVkeHUh?=
ES3	NXzLRVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX2TWM2OD1\|Nz61NFA1KM7:TR?=	MXXTRW5ITVJ?
NCI-H2141	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXU[HRKSzVyPUO4MlA5PDNizszN	NV7Dcnc6W0GQR1XS
MPP-89	NF73dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTR{LkC1PFYh\|ryP	MkLwV2FPT0WU
SK-MEL-2	M3zRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fzW2lEPTB;NEKuOlQxPSEQvF2=	MV3TRW5ITVJ?
LC-1F	NFXNOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTR\|LkO2PFIh\|ryP	NEK5VlRUSU6JRWK=
NH-12	M1LmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDCTWM2OD12Mz65N\|U6KM7:TR?=	Mni5V2FPT0WU
RKO	NGrMR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXDTWM2OD12ND6xNlUzKM7:TR?=	MV;TRW5ITVJ?
KM-H2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7sVotKSzVyPUS0Mlk2PzdizszN	MkThV2FPT0WU
SK-UT-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPzeFRKSzVyPUS5Mlg5OjVizszN	MnHyV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-ERK / ERK; PubMed: 24759734 PLoS One Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control. p-GSK3β / GSK3β / MYCN ; PubMed: 24759734 PLoS One Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines. p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; PubMed: 19244102 Cancer Res Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.	24759734 19244102
Growth inhibition assay	Cell viability; PubMed: 24369536 Biomed Res Int Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.	24369536

In vivo

Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. ^[2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Biochemical Tyrosine Kinase Assays: IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO₄, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl₂ so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl₂ is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO₄ and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research: ^[3]	- Collapse Cell lines: RS4;11, MV4;11, and OC1-AML5 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24 and 48 hours Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors Dosages: ~80 mg/kg Administration: Orally once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	15 mg/mL (28.16 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Sunitinib Malate SDF

Molecular Weight	532.56
Formula	C₂₂H₂₇FN₄O₂.C₄H₆O₅
CAS No.	341031-54-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04669366	Not yet recruiting	Drug: sunitinib\|Drug: axitinib	Kidney Neoplasms	Pfizer	December 15 2020	--
NCT04633122	Recruiting	Drug: Ripretinib\|Drug: Sunitinib	Gastrointestinal Stromal Tumor(GIST)	Zai Lab (Shanghai) Co. Ltd.	November 25 2020	Phase 2
NCT04115189	Active not recruiting	Drug: Sunitinib	Metastatic Renal Cell Carcinoma ( mRCC)	Pfizer	December 13 2019	--
NCT03916458	Completed	--	Carcinoma Renal Cell	Pfizer	December 17 2019	--
NCT04033991	Active not recruiting	Drug: Sunitinib\|Drug: Axitinib	Carcinoma\|Renal Cell	Pfizer	September 27 2019	--
NCT03900793	Recruiting	Drug: Losartan\|Drug: Sunitinib	Osteosarcoma	University of Colorado Denver\|National Cancer Institute (NCI)	August 22 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I was wondering that the compound is in its cis or trans form?
Answer:
S1042 Sunitinib Malate is Z form.
Question 2:
What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?
Answer:
S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Selective VEGFR Inhibitors

Vandetanib (ZD6474) : VEGFR2-selective, IC50=40 nM.
Most Potent VEGFR Inhibitor

Cabozantinib (XL184, BMS-907351) : VEGFR2, IC50=0.035 nM.
FDA-approved VEGFR Inhibitor

Axitinib : Approved by FDA for Renal Cell Carcinoma.
Classic VEGFR Inhibitor

Nintedanib (BIBF 1120) : Potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 3.

Related PDGFR Products

AZD2932 ^New

AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
Sunitinib ^New

Sunitinib (SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib is also a dose-dependent inhibitor of the autophosphorylation activity of IRE1α. Sunitinib induces autophagy and apoptosis.
Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
CP-673451

CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.
Imatinib (STI571)

Imatinib (STI571, CGP057148B, Gleevec) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib (STI571) induces autophagy.
PP121

PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.
Crenolanib (CP-868596)

Crenolanib (CP-868596, ARO 002) is a potent and selective inhibitor of PDGFRα/β with K_d of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src. Crenolanib helps to induce mitophagy.
Tyrphostin AG 1296

Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR. Tyrphostin AG1296 inhibits FGFR and c-Kit with IC50 of 12.3 μM and 1.8 μM in Swiss 3T3 cells. Tyrphostin AG1296 induces dramatic apoptosis in A375R cells.
Sennoside B

Sennoside B, a kind of irritant laxative isolated from rhei rhizome, inhibits PDGF-stimulated cell proliferation.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Sunitinib Malate